Detailed financial statements for AirSculpt Technologies, Inc. (AIRS): income statement, balance sheet and cash-flow summary. Track margins, debt, liquidity and profitability trends year over year with up to 20 years of history.
AirSculpt Technologies, Inc., together with its subsidiaries, focuses on operating as a holding company for EBS Intermediate Parent LLC that provides body contouring procedure services in the United States, Canada, and the United Kingdom. The company offers AirSculpt, a body contouring treatment that removes fat and tightens skin while sculpting targeted areas of the body in a minimally invasive procedure.
Analysis Summary
AirSculpt Technologies, Inc. reported revenue of $151.8M in the most recent fiscal year, growing at a 5-year CAGR of 19.3%.
Trailing-twelve-month margins: gross margin 57.6%, operating margin -7.8%, net margin -7.8%. Free cash flow grew at -41.7% CAGR over 5 years.
At the current price of $2.10, AIRS has negative trailing earnings (P/E not meaningful) and an ROE of -12.52%. Market capitalisation stands at $148M.
Balance sheet quality for AIRS: current ratio of 0.6, net debt of $75.1M. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Income Statement (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $41.2M | $62.8M | $133.3M | $168.8M | $195.9M | $180.3M | $151.8M |
| Cost of Revenue | $15.5M | $23.5M | $44.5M | $58.3M | $74.0M | $71.4M | $61.7M |
| Gross Profit | $25.7M | $39.3M | $88.8M | $110.5M | $121.9M | $109.0M | $90.1M |
| Research & Development | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | $20.1M | $23.6M | $65.7M | $105.9M | $108.3M | $105.6M | $82.2M |
| Operating Expenses | $25.1M | $29.3M | $73.0M | $115.1M | $112.4M | $110.8M | $95.0M |
| Operating Income | $663000 | $10.0M | $15.8M | -$4.5M | $9.5M | -$1.8M | -$4.8M |
| EBITDA | $5.6M | $15.7M | $22.4M | $4.6M | $19.7M | $10.1M | $1.2M |
| Interest Expense | $2.9M | $2.5M | $4.9M | $6.8M | $6.5M | $6.2M | $6.1M |
| Pre-tax Income | -$2.2M | $7.6M | $10.9M | -$11.3M | $3.0M | -$8.1M | -$17.6M |
| Income Tax | 0 | 0 | $329000 | $3.4M | $7.5M | $188000 | -$6.0M |
| Net Income | -$2.2M | $7.6M | $10.6M | -$14.7M | -$4.5M | -$8.3M | -$11.7M |
| EPS | $-0.09 | $0.14 | $-0.01 | $-0.26 | $-0.08 | $-0.14 | $-0.19 |
| EPS (Diluted) | $-0.09 | $0.14 | $-0.01 | $-0.26 | $-0.08 | $-0.14 | $-0.19 |
| Shares Outstanding (Diluted) | $55.6M | $55.6M | $55.6M | $55.7M | $56.8M | $57.7M | $60.5M |
Income Statement (Quarterly)
| Year | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|---|---|---|---|
| Revenue | $35.0M | $33.4M | $39.4M | $42.9M |
| Gross Profit | $22.9M | $19.8M | $20.8M | $23.4M |
| Operating Income | -$9.8M | -$1.5M | -$849000 | $294000 |
| EBITDA | -$3.2M | $2.1M | $1.4M | $3.2M |
| Net Income | -$9.5M | $1.3M | -$2.4M | -$1.1M |
| EPS | $-0.15 | $0.02 | $-0.03 | $-0.02 |
| EPS (Diluted) | $-0.15 | $0.02 | $-0.03 | $-0.02 |
Balance Sheet (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $5.1M | $10.4M | $25.3M | $9.6M | $10.3M | $8.2M | $8.4M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 0 | 0 | 0 | $2.8M | $1.9M | $3.1M | $1.5M |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $6.6M | $11.6M | $29.4M | $16.7M | $16.0M | $17.1M | $15.5M |
| Property, Plant & Equipment | $16.5M | $24.2M | $31.8M | $48.0M | $54.3M | $63.1M | $50.3M |
| Goodwill | $81.7M | $81.7M | $81.7M | $81.7M | $81.7M | $81.7M | $81.7M |
| Intangible Assets | $65.4M | $60.6M | $55.9M | $51.1M | $46.3M | $41.6M | $36.8M |
| Total Assets | $171.5M | $179.6M | $200.6M | $200.8M | $204.0M | $210.0M | $187.3M |
| Accounts Payable | $2.1M | $1.1M | $2.7M | $3.8M | $3.9M | $6.3M | $5.4M |
| Short-term Debt | $400000 | $400000 | $850000 | $2.1M | $2.1M | $4.2M | $5.5M |
| Total Current Liabilities | $8.4M | $9.5M | $16.4M | $22.3M | $20.3M | $28.6M | $27.9M |
| Long-term Debt | $32.3M | $32.1M | $81.8M | $81.4M | $69.5M | $70.5M | $50.6M |
| Total Liabilities | $51.1M | $55.9M | $117.0M | $130.0M | $120.0M | $130.7M | $99.6M |
| Retained Earnings | 0 | 0 | -$393000 | -$15.1M | -$19.6M | -$27.8M | -$40.6M |
| Total Equity | $120.4M | $123.7M | $83.5M | $70.8M | $84.0M | $79.3M | $87.7M |
| Total Debt | $45.1M | $49.8M | $100.6M | $107.6M | $99.7M | $105.1M | $83.6M |
| Net Debt | $40.0M | $39.4M | $75.2M | $98.0M | $89.4M | $96.8M | $75.1M |
| Working Capital | -$1.8M | $2.1M | $13.0M | -$5.6M | -$4.4M | -$11.5M | -$12.4M |
Balance Sheet (Quarterly)
| Year | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|---|---|---|---|
| Cash & Equivalents | $5.4M | $8.4M | $16.7M | $18.8M |
| Total Assets | $185.9M | $187.3M | $192.0M | $193.3M |
| Total Liabilities | $103.8M | $99.6M | $91.7M | $88.4M |
| Total Equity | $82.1M | $87.7M | $100.3M | $104.8M |
| Total Debt | $84.2M | $83.6M | $71.0M | $70.5M |
Cash Flow (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Net Income | -$2.2M | $7.6M | $10.6M | -$14.7M | -$4.5M | -$8.3M | -$11.7M |
| Depreciation & Amortization | $5.0M | $5.6M | $6.6M | $8.1M | $10.3M | $11.9M | $12.8M |
| Stock-based Compensation | $341000 | $325000 | $7.2M | $29.5M | $18.2M | $3.8M | $2.3M |
| Change in Working Capital | $1.6M | $203000 | $771000 | -$1.5M | -$1.4M | $3.8M | -$1.7M |
| Operating Cash Flow | $4.9M | $14.0M | $26.6M | $24.4M | $24.0M | $11.3M | $3.1M |
| Capital Expenditure | -$4.4M | -$3.7M | -$7.1M | -$12.9M | -$9.9M | -$14.0M | -$2.4M |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock Repurchased | 0 | 0 | 0 | 0 | -$233000 | -$903000 | 0 |
| Dividends Paid | -$283000 | -$4.6M | -$66.9M | -$24.3M | -$464000 | -$252000 | 0 |
| Free Cash Flow | $499000 | $10.3M | $19.5M | $11.5M | $14.0M | -$2.7M | $692000 |
Cash Flow (Quarterly)
| Year | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|---|---|---|---|
| Operating Cash Flow | -$225000 | -$2.5M | $5.3M | -$1.2M |
| Capital Expenditure | -$180000 | -$58000 | -$51000 | -$228000 |
| Free Cash Flow | -$405000 | -$2.6M | $5.2M | -$1.5M |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Stock-based Compensation | $1.1M | $3.6M | $559000 | $912000 |
Growth & Margins (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue Growth (YoY) | +52.2% | +112.4% | +26.6% | +16.1% | -7.9% | -15.8% | |
| Net Income Growth (YoY) | +442.5% | +39.3% | -239.1% | +69.5% | -84.2% | -41.4% | |
| EPS Growth (YoY) | +253.2% | -105.1% | -3562.0% | +69.7% | -77.4% | -35.7% | |
| Shares Change (YoY) | +0.0% | +0.0% | +0.1% | +2.0% | +1.6% | +4.8% | |
| FCF Growth (YoY) | +1957.7% | +90.1% | -40.9% | +21.8% | -118.9% | +126.0% | |
| Gross Margin | 62.4% | 62.6% | 66.6% | 65.5% | 62.2% | 60.4% | 59.4% |
| Operating Margin | 1.6% | 16.0% | 11.8% | -2.7% | 4.8% | -1.0% | -3.2% |
| EBITDA Margin | 13.6% | 25.0% | 16.8% | 2.7% | 10.1% | 5.6% | 0.8% |
| Net Margin | -5.4% | 12.1% | 7.9% | -8.7% | -2.3% | -4.6% | -7.7% |
| FCF Margin | 1.2% | 16.4% | 14.6% | 6.8% | 7.2% | -1.5% | 0.5% |
| Effective Tax Rate | -0.0% | 0.0% | 3.0% | -29.9% | 249.4% | -2.3% | 33.9% |
Per-Share Data (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| FCF Per Share | $0.01 | $0.18 | $0.35 | $0.21 | $0.25 | $-0.05 | $0.01 |
| Dividends Per Share | $0.01 | $0.08 | $1.20 | $0.44 | $0.01 | $0.00 | $0.00 |
| Shares Outstanding (Basic) | $55.6M | $55.6M | $55.6M | $55.7M | $56.8M | $57.7M | $60.5M |
What to look at in Healthcare / Pharma
The R&D pipeline is the invisible asset. Patents expiring = revenues evaporating. Look at innovation and cash flow.
- R&D / Revenue — Shows investment in future pipeline. Serious pharma reinvests 15-20%
- 5y EPS growth — After patent expirations, are they still growing?
- Gross margin — Branded pharma >70%. Generics much lower — defines the business type
- FCF / Net Income — Earnings quality — big pharma should convert >90%
- ROIC — Capital reinvested efficiently — key in pharma due to long R&D cycles
- Net debt / EBITDA — Pharma acquisitions pile up debt — watch the post-M&A picture
- P/E vs own 10y history — The best comparison is with its own history, not with peers
Profitability
| Return on Equity | -12.52% |
| Return on Invested Capital | -5.46% |
| Return on Assets | -6.07% |
| Gross Margin | 57.63% |
| Operating Margin | -7.85% |
| Net Margin | -7.79% |
Financial Health
| Debt / Equity | 0.67 |
| Current Ratio | 0.79 |
Key Ratios (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| P/E | -173.85 | 113.50 | -2421.13 | -14.23 | -94.93 | -37.07 | -10.42 |
| P/B | 7.34 | 7.15 | 11.45 | 2.91 | 5.06 | 3.78 | 1.36 |
| P/S | 21.44 | 14.09 | 7.17 | 1.22 | 2.17 | 1.66 | 0.79 |
| Gross Margin | 62.4% | 62.6% | 66.6% | 65.5% | 62.2% | 60.4% | 59.4% |
| Operating Margin | 1.6% | 16.0% | 11.8% | -2.7% | 4.8% | -1.0% | -3.2% |
| Net Margin | -5.4% | 12.1% | 7.9% | -8.7% | -2.3% | -4.6% | -7.7% |
Related companies: AMN · AQST · CMPS · CYH · DRIO · INNV · MLTX
Explore sector: Healthcare · Medical - Care Facilities
More sections of AIRS: Overview · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks